Navigation Links
DuPont Group Vice President Briefs Investors on Performance Materials Segment
Date:12/5/2007

NEW YORK, Dec. 5 /PRNewswire-FirstCall/ -- At a briefing today with security analysts, Diane H. Gulyas, group vice president -- DuPont Performance Materials, discussed the segment's growth and productivity strategies. With more than $6 billion in annual sales, the DuPont Performance Materials platform is delivering customer-driven product innovation and value-added applications development for the global packaging, transportation, electrical and construction markets.

"We have delivered strong revenue and earnings growth by introducing innovative new products and end-use applications, while driving cost productivity," Gulyas said. "Our product innovations have supported price gains and our cost focus has been especially important in light of the significant increase in raw material costs over the past three years. We also have increased our global presence with strong growth in emerging markets.

"We see exciting new growth opportunities that we will pursue by leveraging DuPont polymer, nanotechnology and biotechnology science in photovoltaics, advanced metals replacement and renewable polymers. At the same time, we will continue to deliver valuable, high-performance polymer materials and solutions to our customers at attractive returns on capital," Gulyas said.

Today's presentation can be found at the Investor Center of the company's website at http://www.dupont.com.

DuPont (NYSE: DD) is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in more than 70 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

Forward-Looking Statements: This news release contains forward-looking statements based on management's current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects," "anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in DuPont's filings with the Securities and Exchange Commission, particularly its latest annual report on Form 10-K, as well as others, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions of countries in which the company does business; competitive pressures; successful integration of structural changes, including acquisitions, divestitures and alliances; research and development of new products, including regulatory approval and market acceptance, and seasonality of sales of agricultural products.


'/>"/>
SOURCE DuPont
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. DuPont Focused on Meeting Global Demands for Greater Safety & Protection
2. DuPont Pledges $250,000 to Nature Conservancy for Water Quality Initiative
3. DuPont Scores a Hat Trick for Innovation
4. DuPont Responds to Spelter, W.Va., Lawsuit Decision
5. Broad-based group of physicians calls for improvement in stroke treatment
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. CIGNA Group Insurance Shows Consumers Theres More to Life Through a New Consumer Education Toolkit
8. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. UTC Power Acquires Dome-Tech Group
11. Sutter Health Medical Groups Among the Best for Health Care Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: